Affecting roughly half a million Americans each year, bacterial infections caused by Clostridioides difficile—commonly known as C. diff—are a serious and persistent problem for patients and hospitals ...

Experts are warning about soaring new cases of a deadly bacteria which leaves patients scared with the ‘worst diarrhoea ever’. Clostridioides difficile, or C. diff, infections killed more than one in ...

A new imaging approach used microscopic glowing tags to reveal gene activity in individual C. diff cells in gut tissue samples from infected mice. Here, a resulting image shows a round cross-section ...

Eat foods with probiotics like yogurt and kefir to help replenish good bacteria in your gut. A C. diff diet should include ...

Antibiotics prescribed by dentists may contribute to the growing problem of Clostridium difficile (C. diff), a serious and potentially deadly infection that causes severe diarrhea, suggests research ...

As the effectiveness of antibiotics meant to fight the deadly superbug Clostridioides difficile, or C. diff, wanes, a research team at the University of Houston is seeing positive results of a new ...

There are about half a million C. diff infections every year in the United States. About 30,000 people die from them annually. But if you’ve had C. diff, you’re more likely to get it again. About 1 in ...

Mayo Clinic has added robots in its fight against Clostridium difficile (C-diff) bacteria. In the U.S., C-diff is one of the most common infections patients can get while receiving care at a health ...

New insights into a "friendly virus" that could pave the way for cutting-edge treatments for the potentially fatal superbug C. diff have been uncovered by University of Sheffield scientists. The ...

Drug-resistant superbugs are sickening American hospital patients at an alarming rate — but the reality of these “nightmare bacteria” infections is even worse than the headlines suggest. Last week, ...

SIOUX FALLS, S.D., Aug. 09, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (SABS) (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces ...